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Abstract We are reporting the functional analysis of the S-untranslated region (S’UTR) of human hepatoma HepG2 y-glutamyltransferase (GGT) 
mRNA. Transient expression ofhybrid GGT-luciferase r porter gene mutants in HepG2 shows that this S’UTR acts as a tissue-specific translational 
enhancer. A domain of 173 bases containing asteroid hormone response element (HRE) is responsible for the enhancing effect, which can be amplified 
by addition of dexamethasone at 10e6 M. Furthermore, the regulatory role of the SUTR is demonstrated byinteraction with sense and antisense 
oligonucleotides. 
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1. Introduction 
y-Glutamyltransferase ((5glutamyl)peptide : amino acid 5 
glutamyltransferase, EC 2.3.2.2), a glycosylated plasma mem- 
brane heterodimeric enzyme, implicated in glutathione depend- 
ent detoxification pathways [l] and in leucotriene metabolism, 
is regulated in vivo and in vitro by glucocorticoids [2], thyroid 
hormones [3] and cytokines [4]. GGT activity changes during 
cell differentiation [5] and carcinogenesis [6]. GGT seems also 
to be implicated in signal transduction [7]. Physiopathological 
variations of GGT expression demand a better understanding 
of the regulatory mechanisms at the molecular level. GGT is 
a member of a multigenic family not completely characterized 
located on chromosome 22 [8]. The Y-untranslated region 
(S’UTR) from mRNA coding for human GGT is expressed in 
a tissue-specific manner and presents unusual sizes and organ- 
izations: 669 b for placenta [9], 489 b for HepG2 [lo], 715 b for 
fetal liver [ll], 358 b for pancreas [12] and 424 b for lung [13]. 
Coding regions are highly homologous [12]. 
For a long time UTR were considered of lesser importance 
for the regulation of gene expression but recent developments 
contradict this point of view. In fact S’UTR were shown to 
regulate the expression of a large variety of proteins like 
chicken proto-myb oncogene [14], Xenopus S19 ribosomal pro- 
tein [15], myelin basic protein [16], chicken vitellogenin [17], 
human basic fibroblast growth factor [ 181, glutathione peroxi- 
dase [19], human asparagine synthetase [20] and heat shock 
protein 70 [21] or to interact with protein factors specific to the 
iron response element in the case of the ferritin mRNA S’UTR 
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[22]. 3’UTR from mRNA coding for cytokines and oncogenes 
contain UA-rich seqences able to destabilize mRNA [23] or to 
mediate a translational arrest after Xenopus egg fertilisation 
1241. 
We have previously identified that the SUTR of human 
hepatoma HepG2 GGT mRNA acts as a translational modula- 
tory element and contains a stem-and-loop structure [25]. This 
paper highlights a domain responsible for the novel regulatory 
effect. By this contribution, we extablish a relationship between 
variation of GGT activity after glucocorticoid treatment and 
hormone response elements (HRE) on the S’UTR. Further- 
more, transfection of antisense oligonucleotides has been used 
to inhibit endogenous GGT activity of highly expressing 
HepG2 hepatoma cells, underlining the importance of UTR in 
the regulation of eukaryotic gene expression. 
2. Materials and methods 
2.1. Cells and medium 
HepG2 (human hepatocyte carcinoma) (ECACC) were cultured in 
Dulbecco’s modified Eagle’s medium (G&co-BRL) containing 10% 
(v/v) fetal calf serum (Boehringer Mannheim) and 1% (v/v) antibiotic- 
antimitotic (G&co-BRL). 
2.2. Construction of expression vectors 
Construction of pSVs’-3’Luc and pSV3’-5’Luc containing the com- 
plete 487 b S’UTR (n = 1 to n = 487) of HepG2 GGT mRNA has been 
described previously [25]. In order to construct hree deletion mutants 
of the S’UTR we used the following oligonucleotides: 5’-CCCAAGC- 
‘ITGCAGACCGGGCGTCG-3’ and S-CCCAAGCTTGCGGGTG- 
CAGCCCAA-3’ allow to amplify a 429 bp fragment (A) from n = 58 
to n = 487. S-CCCAAGCTTGCAGACCGGGCGTCG-3’ and S-CC- 
CAAGCTTCAAGGCAATGAGGT-3’ allow to amplify a 357 bp frag- 
ment (B) from n = 130 to n = 487. S-CCCAAGCTTGCAGACCGG- 
GCGTCG-3’ and S-CCCAAGCTTCAGGAGAACGAGAAG-3 
allow to amplify a 187 bp fragment (C) from n = 303 to n = 487. After 
subcloning A, B and C into pSV2Luc linearized by Hind111 (N. E. 
Biolabs), we obtained pSVdlLuc, pSVdzLuc and pSVd3Luc respec- 
tively (Fig. 1). Relevant regions of the tinal constructs were confirmed 
by sequencing in both directions using a T7 sequencing kit (Pharmacia). 
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Other recombinant techniques were carried out according to published 
procedures [26]. 
2.3. Transfection protocol 
Electroporation realized according [27] was as follows: the HepG2 
cells, harvested at 75% confluency after trypsin/EDTA (Gibco-BRL) 
treatment were resuspended in fresh serum-free medium. For each 
experiment, 0.5 x lo6 cells at a concentration of 1.5 x 10’ cells/ml were 
electroporated (725 V/cm and 960 @‘) (Bio-Rad Gene Pulser) with 20 fig 
of each reporter gene construct. Transfections were normalized by 
cotransfection of 15 ,ug pCMV/3 plasmid (Clontech) expressing B-galac- 
tosidase. pGEM-3Z plasmid (Promega) was used as a negative control. 
After transfection, cells were cultured in 10 ml preheated complete 
medium with or without 10m6 M dexamethasone in 0.1% (v/v) ethanol. 
2.4. Reporter gene assays 
Reporter gene analysis was done as described by 1281 with the follow- 
ing modifi&tions: 48. h after transfection the cells were washed with 
cold uhosnhate buffered saline (137 mM NaCl. 2.7 mM KCl. 4.3 mM 
Na,fiPO,: 1.4 mM KH,PO,, pe 7.3) and were lysed in Repdrter lysis 
buffer (Promega). A supematant was prepared after a centrifugation 
of the lysed cells at 14,000 x g for 5 min at 4°C and used for further 
study. 
Light emission resulting from luciferase activity was measured in a 
Lumac-3M luminometer by integration of peak light emisson over 10 s 
at 25°C. Luciferase activity was measured in Luciferase assay buffer 
(Promega) containing 20 mM Tricine, 1.07 mM (MgCO,),Mg(OH),, 
2.67 mM MgSO,, 0.01 mM EDTA, 33.3 mM dithiothreitol, 0.27 mM 
coenzyme A, 0.47 mM luciferin, 0.53 mM ATP and 2 to 10 ~1 of the 
supernatant. 
p-Galactosidase activities were measured in an assay buffer 
(Promega) containing 100 mM sodium phosphate (pH 7.3), 1 mM 
MgCl,, 50 mM p mercaptoethanol, 0,665 mg/ml o-nitrophenyl+-o- 
galactopyranoside and 2-10 ~1 of supernatant. After incubation at 
37°C for 30 min the reaction was stopped with 1 M sodium carbonate 
and optical densities were measured at 405 nm [29]. 
The ratio between arbitrary luciferase light units andg-galactosidase 
activity was expressed per pi of supernatint and was normalized rela- 
tive to the cells transfected with DSV~LUC defined as 100%. Each value 
is the average of the results of at least three independent transfection 
experiments. Assays were repeated twice. 
2.5. Sequence analysis 
FINDPATTERNS was used to search for steroid modulatory ele- 
ments. FRAMES was used to search for open reading frames. These 
programs are included in the Genetics Computer Group package of the 
University of Wisconsin on a Digital Equipment Corporation (DEC) 
MicroVax computer. 
2.6. Oligonucleotide treatments 
HepG2 (ECCAC) were cultured in Dulbecco’s modified Eagle’s me- 
dium (Gibco-BRL) containing 10% (v/v) fetal calf serum (Boehrinaer 
Mannheim) and i% (v/v) aitibioti&aniimitotic (Gibco-BRL). Cells 
were harvested at 75% confluency after trypsin/EDTA (Gibco-BRL) 
treatment and resuspended in fresh serum-free medium. 250 ~1 of 
HepG2 cell suspension were used for transfection at a concentration of 
3 x lo6 cells/ml. 
Unmodified 18-mers were synthetized by Eurogentec (Belgium). 
These are: sense oligonucleotide OL3015’-3’ S-CTTCAGGAGAAC- 
GAGAAG-3’ and antisense oligonucleotide OL3013’-5’ S-CTTCTC- 
GTTCTCCTGAAG-3’. Both are comnlementarv to n = 301 to 320 of 
the SUTR of the HepG2 GGT and w&e introduced in HepG2 cells at 
the final concentration of 5 ,uM and 20 PM by electroporation at 725 
V/cm and 960 fiF (Bio-Rad Gene Pulser). 
2.7. GGT activity 
GGT activity in supernatants was measured by using 6 mM L-Y- 
alutamvl-3-carboxv-4-nitroanilide in 100 mM Tris-HCl. 150 mM 
glycyl-glycine pH s.25 at 37°C [30]. The product of this.reaction, 5 
aminobenzoic acid, is measured at 405 nm. Results are expressed as 
specific activity mU/mg total protein content. 
Protein concentration was measured according to Bradford [31] 
using Bio-Rad reagent with bovine serum albumin as standard. 
psvs’-3’Luc 
pSV3’-5’Luc 
pSVAlLuc 
pSVAzLuc 
303 487 
Fig. 1. Schematic representation of plasmid constructs used for trans- 
fection: pSVS’-3’Luc and pSV3’-5’Luc are harbouring the HepG2 GGT 
SUTR in both orientations, pSVdlLuc, pSVd2Luc and pSVd3Luc are 
deletion mutant plasmids. H = HindIII, B = Bali, S = SM. See section 
2 for details. 
3. Results and discussion 
In order to localize regulatory mRNA elements on the 
HepG2 S’UTR, we constructed three deletion mutants 
pSAlLuc, pSAZLuc and pSA3Luc containing GGT SUTR frag- 
ments of different lengths subcloned upstream of a luciferase 
reporter gene and driven by an SV40 promoter (Fig. 1). These 
constructs as well as the plasmid pSVS’-~‘Luc, containing the 
entire SUTR were introduced into HepG2 cells by electropora- 
tion. The plasmid pSVpga1 expressing B-galactosidase was used 
to normalize transfection efficiency. Forty-eight hours after 
transfection cells were harvested and extracts were prepared to 
measure reporter gene activity. 
Normalized luciferase activities are represented in Fig. 2. The 
results show that luciferase activity presents a 1.7-fold increase 
after transfection of constructs pSVAlLuc (n = 58 to 487) and 
pSVAZLuc (n = 130 to 487) compared to the activity obtained 
after transfection of pSV2Luc. These values correspond to 
those observed for pSVS’-3’Luc containing the entire SUTR 
(n = 1 to 487). According to these results the 357 b most prox- 
imal to the AUG are sufficient to induce the enhancing effect 
of the S’UTR from the human hepatoma HepG2 GGT mes- 
sage. The third deletion mutant, pSVA3Luc (n = 303 to 487), 
does not show any enhancement of the luciferase activity and 
gives similar luciferase activity as the pSV2Luc control plasmid 
without GGT mRNA insert. This construct is missing 173 b 
which are vital for the observed positive regulation of the trans- 
lation of this hybrid mRNA in human HepG2 hepatoma cells. 
This region is also implicated in the formation of the secondary 
structure previously described [25]. Deleting the sequences re- 
sponsible for this secondary structure results in a reduced trans- 
lation of the luciferase RNA and explains the loss of reporter 
gene activity after transfection of pSVA3Luc. pSVA2Luc 
contains the relevant sequence messages and allows the same 
translation efficiency as pSVAlLuc or pSVS’-3’Luc. Regulatory 
elements are then situated between n = 130 and n = 303. Com- 
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Fig. 2. The effect of deletions in the HepG2 GGT S’UTR on luciferase 
activity in the transfected human hepatoma HepG2 cell line: For each 
assay, results are expressed as a percentage of normalized luciferase 
activity with 100% for pSV2Luc. Each bar represents the 
mean f S.E.M. of at least three independent experiments. Assays were 
repeated twice. 
puter analysis of these 173 b located a steroid hormone re- 
sponse element (AGAAGA) previously described by Verdi et 
al. [ 161. This element is localized on the different GGT mRNAs 
coding for human pancreas at the position n = 214 [12] and 
placenta at n = 524 [9] and for rat kidney clone 17 at n = 97 [32]. 
This element is not found in the human fetal liver mRNA [ 111, 
rat kidney clone 12 [32] or rat hepatoma mRNA [33]. Glucocor- 
ticoid hormones have previously been shown to be able to 
enhance GGT activity in vivo in rodents [2] as well as in humans 
[34]. We used the pSVS’-3’Luc and pSV3’-S’Luc constructs 
which were transfected into HepG2 cells and treated the trans- 
fected cells with 10e6 M dexamethasone. Cells were harvested 
48 h after transfection and luciferase activity was measured. 
Results are represented in Fig. 3. The results show clearly that 
administration of dexamethasone further enhances the lucif- 
erase activity by 3.6-fold compared to the increase of the con- 
trol transfection without 10m6 M dexamethasone in the presence 
Table 1 
Inhibitory effect of sense and antisense oligonucleotides on GGT ex- 
pression and on stimulation of luciferase activity by the S’UTR 
Treatment Luciferase activity GGT specific activity 
(light unit@) (nmol/min/mg protein) 
None 227 f 20 260 + 18 
(%) (100 f 9) (100 f 7) 
OL3015’-3’ (5 PM) 224 f 21 268 f 8 
(8) (98 f 9) (103 + 3) 
OL3013’-5’ (5 PM) 156 f 15 176 f 24 
(%) (69 f 7) (68 f 9) 
OL3015’-3’ (20 PM) 230 f 17 251 f 33 
(%) (101 f 7) (97 f 13) 
OL3013’-5’ (20 PM) 144f19 119 It 11 
(%) (64+8) 46 + 4 
Luciferase activity is expressed in HepG2 cells cotransfected with 
pSVS’-3’Luc as the ratio of arbitrary light units/units of /Cgalactosi- 
dase/pl of sample x 10’. In brackets, GGT and luciferase activities are 
expressed as a percentage with 100% for mock transfected cells. All 
results are expressed as a mean f S.E.M. of at least three independent 
experiments. Assays were done in duplicate. See section 2 for details. 
of 0.1% (v/v) ethanol. These results partially explain the action 
of glucocorticoid hormones on the expression of GGT. Shapiro 
et al. [35] showed a stabilizing activity of steroid hormones, 
reducing the degradation of vitellogenin mRNA in Xenopus 
oocytes. 
The constructs presenting the SUTR in the non-physiologi- 
cal 3’-5’ orientation (construct pSV3’-5’Luc) do not show mod- 
ulation of luciferase activity. This type of construct presents 
two upstream open reading frames giving rise to two potential 
small peptides of 12, respectively 14 amino acids. These up- 
stream reading frames might be an explanation for the residual 
luciferase activity of the pSV3’-5’Luc constructs with or with- 
out dexamethasone treatment. Synthesis of upstream leader 
peptides is already known to modify translation of the yeast 
protein GCN4 [36] and of the p2 adrenergic receptor [37]. 
At this point of our investigations, in order to acertain the 
regulatory role of the S’UTR, we targeted a region of the 
5’UTR from human hepatoma HepG2 mRNA between  = 301 
and n = 320 with sense and antisense oligonucleotides (Table 
1). We estimated the effect of those oligonucleotides first by 
cotransfecting sense or antisense oligonucleotides and the lucif- 
erase construct pSVS’-3’Luc. Compared to mock-transfected 
HepG2 with pSVS’-3’Luc or pSV2Luc, addition of OL3013’-5’ 
at a 5 ,uM and 20 PM concentration results in a 3 1% and 37% 
decrease of the luciferase activity respectively. Transfection of 
sense OL3015’-3’ did not significantly alter the expression of 
luciferase in the HepG2 hepatoma cells. We then modulated 
endogenous GGT expression in highly expressing HepG2 
hepatoma (Table 1) . This tool allows further investigation of 
the physiological importance of GGT related to glutathione 
metabolism. After electroporation of sense and antisense ol- 
igonucleotides into HepG2 cells, we observed a 32% and 54% 
decrease of endogenous GGT specific activity after administra- 
tion of OL3013’-5’ at 5 PM and 20 PM, respectively. No change 
of GGT specific activity after administration of OL3015’-3’ 
could be detected when compared to mock-transfected cells . 
Currently, we cannot inhibit the GGT activity of HepG2 cells 
completely possibly because other mRNAs coding for GGT 
present alternative SUTR lacking the OL3013’-5’ target se- 
quence. Other oligonucleotides as well as factors known to 
regulate GGT expression against HepG2 mRNAs are under 
investigation. 
pSV2Luc 
pSVB’-3’Luc 
pSA3 
PSM 
pSA1 
Luciferase activity (%) 
Fig. 3. The effect of 10m6 M dexamethasone on luciferase activity in the 
human hepatoma HepG2 cell line: For each assay, results are expressed 
as a percentage of normalized luciferase activity with 100% for 
pSV2Luc. Each bar represents the mean f S.E.M. of at least three 
independent experiments. Assays were repeated twice. 
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